Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small cell lung cancer.

George R Simon1, Henry Wagner,

  • 1Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Suite 3170, Tampa, FL 33612, USA. Simongr@moffitt.usf.edu

Chest
|January 16, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer Analysis.

Cancers·2026
Same author

Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions.

Biomolecules·2026
Same author

Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung Cancer.

JAMA network open·2026
Same author

PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017-2021.

Journal of immunotherapy and precision oncology·2025
Same author

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Nature communications·2025
Same author

Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung Cancer.

JCO clinical cancer informatics·2024
Same journal

A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy.

Chest·2026
Same journal

Independent Prognostic Contributions of Anti-Ro52 and Anti-MDA5 in Autoimmune-Associated Interstitial Lung Disease.

Chest·2026
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
Same journal

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
Same journal

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept.

Chest·2026
See all related articles

Small cell lung cancer (SCLC) staging involves CT scans, bone, and brain imaging. Treatment varies by stage, with limited-stage SCLC offering a potential cure, while extensive-stage SCLC has a poorer prognosis.

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Imaging

Background:

  • Small cell lung cancer (SCLC) proportion has declined.
  • SCLC is classified into limited-stage and extensive-stage disease.
  • Standard staging includes CT scans (chest/abdomen), bone scans, and brain imaging (CT/MRI).

Framework:

  • Limited-stage SCLC: Curative intent with chemotherapy and radiation therapy.
  • Extensive-stage SCLC: Primarily chemotherapy, with high initial response rates but shorter median survival.
  • Prophylactic cranial irradiation recommended for complete remission patients.

Implementation:

  • Current SCLC treatment guidelines focus on chemotherapy and radiation.
  • Positron emission tomography (PET) scanning's role in SCLC staging requires further definition.

Related Experiment Videos

  • Maintenance therapy and bone marrow transplantation are not indicated for SCLC.

    • Implications:

    • Evidence-based guidelines for SCLC staging and treatment are crucial for clinical practice.
    • Understanding SCLC staging and treatment outcomes informs patient management and prognosis.
    • Ongoing research may refine SCLC staging and treatment protocols.